Page last updated: 2024-12-04

5,8,11-eicosatriynoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5,8,11-eicosatriynoic acid: a lipoxygenase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5,8,11-icosatriynoic acid : A C20 polyunsaturated fatty acid having three triple bonds in the 5-, 8- and 11-positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1781
CHEMBL ID1449344
CHEBI ID53454
SCHEMBL ID68425
MeSH IDM0087224

Synonyms (52)

Synonym
CBIOL_001862
5,8,11-eicosatriynoic acid
LMFA01030696
BIO2_000651
BIO1_001126
BIO1_000148
BIO1_000637 ,
BIO2_000171
IDI1_033921
BSPBIO_001451
ETI ,
5,8,11-eicosatriynoic acid, >=98%
NCGC00161330-02
NCGC00161330-01
KBIO3_000341
KBIO3_000342
KBIO2_005307
KBIO2_000171
KBIOSS_000171
KBIO2_002739
KBIOGR_000171
NCGC00161330-03
HMS1989I13
BML2-F03
HMS1361I13
HMS1791I13
5,8,11-eicosatriyenoic acid
5,8,11-icosatriynoic acid
13488-22-7
eicosa-5,8,11-triinsaeure
icosa-5,8,11-triynoic acid
5,8,11-eti
CHEBI:53454 ,
r7eu6ly7hj ,
unii-r7eu6ly7hj
5,8,11-eicosatriynoicacid
SCHEMBL68425
CHEMBL1449344
HMS3649H03
HMS3402I13
mfcd00077343
DTXSID10159018
5,8,11,-eicosatriynoic acid
J-006619
FT-0705856
Q27124059
sr-01000946657
SR-01000946657-1
eicosatriynoic acid, 5,8,11-
PD020546
HY-124252
CS-0086037

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"5 g resting tensions, NOS inhibitors shifted the ACh dose-response curve to the right."( Mechanical stretch reveals different components of endothelial-mediated vascular tone in rat aortic strips.
Bani, D; Ciuffi, M; Failli, P; Franchi-Micheli, S; Mazzetti, L; Zilletti, L, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitorA lipoxygenase inhibitor that interferes with the action of arachidonate 12-lipoxygenase (EC 1.13.11.31).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
polyunsaturated fatty acidAny fatty acid containing more than one double bond. Acids in this group are reported to have cardioprotective effects; and levels are lowered in chronic fatigue syndrome.
icosanoidAny member of the group of signalling molecules arising from oxidation of the three C20 essential fatty acids (EFAs) icosapentaenoic acid (EPA), arachidonic acid (AA) and dihomo-gamma-linolenic acid (DGLA).
long-chain fatty acidA fatty acid with a chain length ranging from C13 to C22.
acetylenic fatty acidAny unsaturated fatty acid containing at least one triple bond in the carbon chain framework.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency44.66840.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency39.81070.004023.8416100.0000AID485290
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency19.95260.125919.1169125.8920AID2549
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency7.94330.354828.065989.1251AID504847
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (44.44)18.7374
1990's6 (22.22)18.2507
2000's5 (18.52)29.6817
2010's2 (7.41)24.3611
2020's2 (7.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.25 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]